Trends and Predictors of Antihypertensive Medication Adherence in Commercially Insured Adults under 65 (2018-2023).

ABSTRACT: Understanding class-specific antihypertensive adherence is crucial for optimizing hypertension management. This retrospective cohort study analyzed adherence to antihypertensive medication among commercially insured adults (18-64 years) from 2018 to 2023 using Merative MarketScan data. Adherence was defined as the proportion of days covered (PDC) ≥ 80%. Among 2 770 855 hypertensive patients with single-pill therapy, the majority were older (43% aged 55-64 years) and predominantly male (53%). The South had the highest prevalence of hypertension (53%). Overall adherence improved significantly from 56.61% in 2018-2019 to 75.55% in 2022-2023 across all medication classes. Patients receiving angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) combination therapies ha

SUBMITTER: Bhuiya NMMA 

PROVIDER: S-EPMC12317324 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature